Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. The gene discussed is BCR; the disease is acute myeloid leukemia.